Skip to main content

Metabolic Disorders

Discovery Services

Select Service Type

DIABETES

  • Pancreatic Lipase inhibitionDRF/CB/MD-01

    Pancreatic Lipase inhibition to evaluate Diabetes (Type II) using cell-free enzyme assay, measuring Lipase inhibition.

    • Cell Model

      Cell-free Enzyme assay

    • End Point

      Lipase inhibition

    • Reference Drugs

      Orlistat

    • Relevance

      Diabetes (Type II)
  • Alpha Amylase inhibitionDRF/CB/MD-02

    Alpha Amylase inhibition to evaluate Diabetes (Type II) using cell-free enzyme assay, measuring Alpha Amylase inhibition.

    • Cell Model

      Cell-free Enzyme assay

    • End Point

      Alpha Amylase inhibition

    • Reference Drugs

      Acarbose

    • Relevance

      Diabetes (Type II)
  • Alpha Glucosidase inhibitionDRF/CB/MD-03

    Alpha Glucosidase inhibition to evaluate Diabetes (Type II) using cell-free enzyme assay, measuring Alpha Glucosidase inhibition.

    • Cell Model

      Cell-free Enzyme assay

    • End Point

      Alpha Glucosidase inhibition

    • Reference Drugs

      Acarbose and Miglitol

    • Relevance

      Diabetes (Type II)
  • Glucose uptake in adipocytes/muscle/liver cell lineDRF/CB/MD-04

    Glucose uptake in adipocytes/muscle/liver cell line to evaluate Diabetes (Type II) using Adipocytes (3T3-L1) / Muscle (C2C12)/ liver (HepG2) cell line, measuring Glucose uptake by NBDG.

    • Cell Model

      Adipocytes (3T3-L1) / Muscle (C2C12)/ liver (HepG2) cell line

    • End Point

      Glucose uptake by NBDG

    • Reference Drugs

      Insulin

    • Relevance

      Diabetes (Type II)
  • Adipogenesis/lipid accumulation inhibition in adipocytes/muscle/liver cellsDRF/CB/MD-05

    Adipogenesis/lipid accumulation inhibition in adipocytes/muscle/liver cells to evaluate Diabetes (Type II) using Adipocytes (3T3-L1), measuring Lipid content by Oil O red.

    • Cell Model

      Adipocytes (3T3-L1)

    • End Point

      Lipid content by Oil O red

    • Reference Drugs

      Simvastatin

    • Relevance

      Diabetes (Type II)
  • Adipolysis (FFA/glycerol release) in adipocytesDRF/CB/MD-06

    Adipolysis (FFA/glycerol release) in adipocytes to evaluate Diabetes (Type II) using Adipocytes (3T3-L1), measuring Glycerol release.

    • Cell Model

      Adipocytes (3T3-L1)

    • End Point

      Glycerol release

    • Reference Drugs

      Insulin

    • Relevance

      Diabetes (Type II)
  • Adiponectin release in adipocytesDRF/CB/MD-07

    Adiponectin release in adipocytes to evaluate Diabetes (Type II) using Adipocytes (3T3-L1), measuring Adiponectin levels.

    • Cell Model

      Adipocytes (3T3-L1)

    • End Point

      Adiponectin levels

    • Reference Drugs

      Insulin

    • Relevance

      Diabetes (Type II)
  • Cytokines inhibition in adipocytesDRF/CB/MD-08

    Cytokines inhibition in adipocytes to evaluate Diabetes (Type II) using Adipocytes (3T3-L1), measuring Cytokines inhibition.

    • Cell Model

      Adipocytes (3T3-L1)

    • End Point

      Cytokines inhibition

    • Reference Drugs

      Dexamethasone/ Statins

    • Relevance

      Diabetes (Type II)
  • Proliferation inhibition in pancreatic beta cells (RIN- 5F)DRF/CB/MD-09

    Proliferation inhibition in pancreatic beta cells (RIN- 5F) to evaluate Diabetes (Type I) using pancreatic beta cells (RIN- 5F), measuring Inhibition of proliferation.

    • Cell Model

      pancreatic beta cells (RIN- 5F)

    • End Point

      Inhibition of proliferation

    • Reference Drugs

      Quercetin/ Silymarin

    • Relevance

      Diabetes (Type I)
  • Protection against cytokine induced damage in pancreatic beta cells (RIN-5F)DRF/CB/MD-10

    Protection against cytokine induced damage in pancreatic beta cells (RIN-5F) to evaluate Diabetes (Type I) using pancreatic beta cells (RIN- 5F), measuring restoration of cell viability.

    • Cell Model

      pancreatic beta cells (RIN- 5F)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      Quercetin/ Silymarin

    • Relevance

      Diabetes (Type I)
  • Insulin release in pancreatic beta cells (RIN-5F)DRF/CB/MD-11

    Insulin release in pancreatic beta cells (RIN-5F) to evaluate Diabetes (Type I) using pancreatic beta cells (RIN- 5F), measuring Insulin release.

    • Cell Model

      pancreatic beta cells (RIN- 5F)

    • End Point

      Insulin release

    • Reference Drugs

      Emodin

    • Relevance

      Diabetes (Type I)
  • Expression of GLUT-1 receptorsDRF/CB/MD-12

    Expression of GLUT-1 receptors to evaluate Diabetes (Type I) using receptor overexpressing cells, measuring Agonist/ Antagonist activity.

    • Cell Model

      Receptor Overexpressing cells

    • End Point

      Agonist/ Antagonist activity

    • Reference Drugs

      Insulin

    • Relevance

      Diabetes (Type I)
  • Biomarker analysis by multiplexingDRF/CB/MD-13

    Biomarker analysis by multiplexing to evaluate Diabetes (Type I) using pancreatic beta cells (RIN- 5F), measuring modulation of key markers.

    • Cell Model

      pancreatic beta cells (RIN- 5F)

    • End Point

      Modulation of key markers

    • Reference Drugs

      Dexamethasone/ Celecoxib

    • Relevance

      Diabetes (Type I)

HYPERLIPIDEMIA / NASH / NAFLD

  • Pancreatic Lipase inhibitionDRF/CB/MD-14

    Pancreatic Lipase inhibition to evaluate Hyperlipidemia/NASH/NA FLD using lipase from Porcine pancreas, measuring inhibition in lipase enzyme activity.

    • Cell Model

      Lipase from Porcine pancreas

    • End Point

      Inhibition in Lipase enzyme activity

    • Reference Drugs

      Orlistat

    • Relevance

      Hyperlipidemia/NASH/NA FLD
  • Alpha Amylase inhibitionDRF/CB/MD-15

    Alpha Amylase inhibition to evaluate Hyperlipidemia/NASH/NA FLD using α-amylase from Aspergillus oryzae, measuring inhibition in amylase enzyme activity.

    • Cell Model

      α-amylase from Aspergillus oryzae

    • End Point

      Inhibition in amylase enzyme activity

    • Reference Drugs

      Acarbose /Quercetin

    • Relevance

      Hyperlipidemia/NASH/NA FLD
  • FFA induced Adipogenesis/lipid accumulation inhibition in adipocytes/liver cellsDRF/CB/MD-16

    FFA induced Adipogenesis/lipid accumulation inhibition in adipocytes/liver cells to evaluate Hyperlipidemia/NASH/NA FLD using Hepatocytes (HepG2), measuring Lipid accumulation by Oil-O Red.

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      Lipid accumulation by Oil-O Red

    • Reference Drugs

      Atorvastatin calcium salt/ simvastatin

    • Relevance

      Hyperlipidemia/NASH/NA FLD
  • Inhibition of cholesterol synthesisDRF/CB/MD-17

    Inhibition of cholesterol synthesis to evaluate Hyperlipidemia/NASH/NA FLD using Hepatocytes (HepG2), measuring inhibition in cholesterol .

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      Inhibition in cholesterol

    • Reference Drugs

      Atorvastatin calcium salt/ simvastatin

    • Relevance

      Hyperlipidemia/NASH/NA FLD
  • HMG-CoA reductaseDRF/CB/MD-18

    HMG-CoA reductase to evaluate Hyperlipidemia/NASH/NA FLD using HMG-CoA enzyme (cell free), measuring Inhibition of HMG-CoA enzyme activity.

    • Cell Model

      HMG-CoA enzyme (cell free)

    • End Point

      Inhibition of HMG-CoA enzyme activity

    • Reference Drugs

      Atorvastatin calcium salt/ simvastatin

    • Relevance

      Hyperlipidemia/NASH/NA FLD
  • Biomarker analysis by multiplexingDRF/CB/MD-19

    Biomarker analysis by multiplexing to evaluate Hyperlipidemia/NASH/NA FLD using Hepatocytes (HepG2), measuring cytokine inhibition.

    • Cell Model

      Hepatocytes (HepG2)

    • End Point

      Cytokine inhibition

    • Reference Drugs

      Atorvastatin calcium salt/ simvastatin

    • Relevance

      Hyperlipidemia/NASH/NA FLD

MITOCHONDRIAL BIOLOGY -ENERGY BOOSTING, STAMINA BUILDING, ANTI-FATIGUE

  • Formation of myotubes in muscle cells (C2C12)DRF/CB/MB-01

    Formation of myotubes in muscle cells (C2C12) to evaluate energy booster using Murine Myoblast cells(C2C12), measuring increase in myotube formation .

    • Cell Model

      Murine Myoblast cells(C2C12)

    • End Point

      Increase in myotube formation

    • Reference Drugs

      Resveratrol

    • Relevance

      Energy booster
  • Cytoprotection in muscle cells (C2C12) against oxidative stressDRF/CB/MB-02

    Cytoprotection in muscle cells (C2C12) against oxidative stress to evaluate energy using Murine Myoblast cells(C2C12), measuring restoration of cell viability.

    • Cell Model

      Murine Myoblast cells(C2C12)

    • End Point

      Restoration of cell viability

    • Reference Drugs

      N-Acetyl Cysteine

    • Relevance

      Energy booster/Stamina/ Anti- fatigue
  • Apoptosis in muscle cells (C2C12) against oxidative stressDRF/CB/MB-03

    Apoptosis in muscle cells (C2C12) against oxidative stress in Murine Myoblast cells(C2C12) to study Energy booster/Stamina/Anti- fatigue.

    • Cell Model

      Murine Myoblast cells(C2C12)

    • End Point

      Anti-apoptotic potential against damage

    • Reference Drugs

      Resveratrol

    • Relevance

      Energy booster/Stamina/Anti- fatigue
  • Mitochondrial membrane potential (MMP) in muscle cells (C2C12)DRF/CB/MB-04

    Mitochondrial membrane potential (MMP) in muscle cells (C2C12) to evaluate Energy booster/Stamina/Anti- fatigue using Murine Myoblast cells(C2C12), measuring mitochondrial membrane potential by JC-1.

    • Cell Model

      Murine Myoblast cells(C2C12)

    • End Point

      Mitochondrial membrane potential by JC-1

    • Reference Drugs

      Resveratrol/ Rutin

    • Relevance

      Energy booster/Stamina/Anti- fatigue
  • Increased ATP synthesis in muscle cells (C2C12)DRF/CB/MB-05

    Increased ATP synthesis in muscle cells (C2C12) to evaluate energy using Murine Myoblast cells(C2C12), measuring increase in ATP content.

    • Cell Model

      Murine Myoblast cells(C2C12)

    • End Point

      Increase in ATP content

    • Reference Drugs

      Resveratrol

    • Relevance

      Energy booster/Stamina/Anti- fatigue
  • Enhanced thermogenesis by increase in mitochondrial mass in C2C12 cells (NAO staining)DRF/CB/MB-06

    Enhanced thermogenesis by increase in mitochondrial mass in C2C12 cells (NAO staining) to evaluate Energy booster/ Stamina/Anti- fatigue using Murine Myoblast cells(C2C12), measuring Mitochondrial mass.

    • Cell Model

      Murine Myoblast cells(C2C12)

    • End Point

      Mitochondrial mass

    • Reference Drugs

      Resveratrol/ Rutin

    • Relevance

      Energy booster/ Stamina/Anti- fatigue
  • Migration potential in muscle cells (C2C12)DRF/CB/MB-07

    Migration potential in muscle cells (C2C12) to evaluate Energy booster/ Stamina/Anti- fatigue using Murine Myoblast cells(C2C12), measuring percent modulation of migration.

    • Cell Model

      Murine Myoblast cells(C2C12)

    • End Point

      Percent modulation of migration

    • Reference Drugs

      Resveratrol

    • Relevance

      Energy booster/ Stamina/Anti- fatigue
  • Calcium efflux in muscle cells (C2C12)DRF/CB/MB-08

    Calcium efflux in muscle cells (C2C12) in Murine Myoblast cells(C2C12) to study Energy booster/ Stamina/Anti- fatigue.

    • Cell Model

      Murine Myoblast cells(C2C12)

    • End Point

      Calcium efflux

    • Reference Drugs

      Alpha-methylprednisolone (PDN)/ Deflazacort

    • Relevance

      Energy booster/ Stamina/Anti- fatigue
  • Plasmid DNA protection against oxidative/UVB induced DNA damageDRF/CB/MB-09

    Plasmid DNA protection against oxidative/UVB induced DNA damage to evaluate Energy booster/ Stamina/Anti-fatigue using Plasmid DNA from PBR322 Ecoli, measuring Restoration of Supercoiled DNA.

    • Cell Model

      Plasmid DNA from PBR322 E-coli

    • End Point

      Restoration of Supercoiled DNA

    • Reference Drugs

      Trolox

    • Relevance

      Energy booster/ Stamina/Anti-fatigue
  • Biomarker analysis by multiplexingDRF/CB/MB-10

    Biomarker analysis by multiplexing to evaluate Energy booster/ Stamina/Anti-fatigue using Murine Myoblast cells(C2C12), measuring modulation of key biomarkers involved. l .

    • Cell Model

      Murine Myoblast cells(C2C12)

    • End Point

      Modulation of key biomarkers involved

    • Reference Drugs

      Resveratrol

    • Relevance

      Energy booster/ Stamina/Anti-fatigue

GPCR/NUCLEAR RECEPTOR

  • Cell based GPCR Profiling services (panel available on request)DRF/CB/MB-11

    Cell based GPCR Profiling services (panel available on request) to evaluate multiple therapeutic areas using GPCR over-expressing cell lines, measuring Agonist/ antagonist activity.

    • Cell Model

      GPCR over-expressing cell lines

    • End Point

      Agonist/ antagonist activity

    • Reference Drugs

      Based on the selected receptor

    • Relevance

      Multiple Therapeutic areas
  • Nuclear Receptor profiling services (panel available on request)DRF/CB/MB-12

    Nuclear Receptor profiling services to evaluate Multiple Therapeutic areas using Nuclear Receptor over-expressing cell lines, measuring Agonist/ antagonist activity.

    • Cell Model

      Nuclear Receptor over-expressing cell lines

    • End Point

      Agonist/ antagonist activity

    • Reference Drugs

      Based on the selected receptor

    • Relevance

      Multiple Therapeutic areas
  • STZ induced type-I diabetic modelPCY/MD-01

    STZ-induced type-I diabetes model in rats, assessing blood glucose levels (BGL), oral glucose tolerance test (OGTT), insulin level, and pancreas histology.

    • Animal Model

      Wistar/SD Rats

    • End Point

      BGL, OGTT, Insulin level, Histology of pancreas, Body weight, Feed consumption

    • Reference Drugs

      Insulin
  • STZ induced type-II diabetes in Wistar/SD Rat pups (Neonatal model & High Fat Diet)PCY/MD-02

    STZ-induced type-II diabetes in rats (neonatal model & high-fat diet), measuring BGL, OGTT, insulin levels, and pancreas histology

    • Animal Model

      Wistar/SD Rats

    • End Point

      BGL, OGTT, Insulin level, Histology of pancreas, Body weight, Feed consumption

    • Reference Drugs

      Metformin
  • Anti-Obesity Activity in High Fat Diet modelPCY/MD-03

    Anti-obesity activity in high-fat diet model in mice, evaluating BGL, OGTT, lipid profile, body weight, and feed consumption.

    • Animal Model

      C57BL/6 Mice

    • End Point

      BGL, OGTT, Lipid profile, Body weight, Feed consumption

    • Reference Drugs

      Orlistat
  • Evaluation of Anti-Hyperglycemic Potential through Normoglycemic Testing and Oral Glucose Tolerance Test (OGTT)PCY/MD-04

    Evaluation of anti-hyperglycemic potential through normoglycemic testing and OGTT in rats, measuring blood glucose levels and AUC

    • Animal Model

      Wistar/SD Rats

    • End Point

      Blood glucose level, AUC

    • Reference Drugs

      `--
  • Vit.D3 deficiency induced abnormalities modelPCY/MD-05

    Vitamin D3 deficiency-induced abnormalities model in rats, assessing vitamin D metabolites, calcium, potassium, and behavior using Y-maze test.

    • Animal Model

      Wistar/SD Rats

    • End Point

      Vitamin D metabolites estimation, Calcium, Potassium in plasma, Behavioural memory Y maze test,

    • Reference Drugs

      Calciferol
  • Anti-ageing activity using D-Galactose induced modelPCY/MD-06

    Anti-aging activity using D-Galactose-induced model in rats, measuring body weight, antioxidants in serum and vital organs, and histology.

    • Animal Model

      Wistar/SD Rats

    • End Point

      Body weight, Antioxidants in serum & vital organs, Histology of vital organs

    • Reference Drugs

      `--
  • Diabetes induced severe oxidative stress modelPCY/MD-07

    Diabetes-induced severe oxidative stress model in rats, assessing BGL, SOD, catalase, GPX, and GSH levels in plasma and tissues.

    • Animal Model

      Wistar/SD Rats

    • End Point

      BGL, SOD, Catalase, GPX, GHS, etc. in plasma and tissues

    • Reference Drugs

      Curcumin
  • Model for Testosterone Release through Orchiectomy (ORX)PCY/MD-08

    Model for testosterone release through orchiectomy (ORX) in rats, measuring testosterone release kinetics and histology.

    • Animal Model

      Wistar/SD Rats

    • End Point

      Testosterone release kinetics,

    • Reference Drugs

      `--
  • PTU & Levothyroxine induced Hypothyroidism and Hyperthyroidism modelPCY/MD-09

    PTU & levothyroxine-induced hypothyroidism and hyperthyroidism model in rats, assessing T3, T4, TSH levels, and thyroid histology.

    • Animal Model

      Wistar/SD Rats

    • End Point

      Feed intake, Water intake, Body weight, T3 T4, TSH levels, Histology of thyroid gland

    • Reference Drugs

      Levothyroxine & Propylthiouracil
  • Anti-diabetic activity using db/db Mice modelPCY/MD-10

    Anti-diabetic activity using db/db mice model, measuring BGL, insulin, body weight, OGTT, and pancreas histology.

    • Animal Model

      db/db Mice

    • End Point

      Blood Glucose level, Insulin

    • Reference Drugs

      Metformin